Adjuvant Bevacizumab Fails to Help in High-Risk Breast Cancer

The addition of bevacizumab to adjuvant chemotherapy regimens does not improve survival in women with high-risk breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists explains the results from the SOPHIA trial, a phase III study of chemotherapy plus margetuximab or trastuzu... Author: obr Added: 06/26/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
We report a 76-year-old patient who was diagnosed with concurrent accessory breast and primary lung cancer, both were positive for somatic BRCA-2 (E1593D) mutation. He received concurrent radiation and platinum-based chemotherapy for lung cancer with good response, but breast cancer progressed in about 8 months, and further progressed after single agent anastrozole in 10 months. Next Generation Sequencing (NGS) of breast cancer was also positive forCCND1 (Cyclin D1) and FGFR1 amplifications. Despite a poor molecular profile of breast cancer, and progression following platinum-based chemotherapy and anastrozole, he was succ...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
We describe the recent advances in clinical development of anti-HER2 treatments. To this aim, we used literature search via Pubmed and made an inventory of abstracts published during the last two years in major oncology conferences. Expert opinion: Further changes will probably occur during the next decade in the management of metastatic HER2-positive breast cancer. This is mainly driven by the fact that the two mainstay drugs (pertuzumab and TDM-1) that confer prolonged survival (56 months) to these patients are currently being used in the treatment of early-stage disease in a subset of patients. Thus, there is an urgent ...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
Publication date: Available online 25 June 2019Source: Meta GeneAuthor(s): Roby Will Vencatto, Susana Ramalho, Fernando Augusto Lima Marson, Luciana Montes Rezende, Stéphanie Villa-Nova Pereira, Luciana Cardoso Bonadia, Carmen Silvia Passos Lima, Carmen Silvia BertuzzoAbstractBreast cancer (BC) is the second most prevalent type of cancer worldwide and the most common among women. Also, BC shows different subtypes and patterns of chemotherapy response. Moreover, BC recurrence pattern is not well knowledge. But, genetic variants can alter drug pharmacokinetics and pharmacodynamics with an impact in treatment outcome. ...
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research
ConclusionAlmost all patients with ILRR were operated. Especially patients with hormone receptor-negative recurrent breast cancer seemed to show a benefit having been treated with chemotherapy. Most patients were without recurrence after their particular therapies.
Source: Archives of Gynecology and Obstetrics - Category: OBGYN Source Type: research
Authors: Tadayyon H, Gangeh M, Sannachi L, Trudeau M, Pritchard K, Ghandi S, Eisen A, Look-Hong N, Holloway C, Wright F, Rakovitch E, Vesprini D, Tran WT, Curpen B, Czarnota G Abstract We demonstrate the clinical utility of combining quantitative ultrasound (QUS) imaging of the breast with an artificial neural network (ANN) classifier to predict the response of breast cancer patients to neoadjuvant chemotherapy (NAC) administration prior to the start of treatment. Using a 6 MHz ultrasound system, radiofrequency (RF) ultrasound data were acquired from 100 patients with biopsy-confirmed locally advanced breast cancer...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
(Baylor College of Medicine) Researchers develop molecular testing to distinguish patients who may need less from those who may need more therapy for HER2 positive breast cancer.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
uyu Hui Yue Yin Triple-negative breast cancer (TNBC) lacks major effective target molecules and chemotherapy remains the current main treatment. However, traditional chemotherapy drugs, such as doxorubicin (DOX), cause serious side effects and have a poor prognosis. Piperlongumine (PL), a natural alkaloid, has showed selective anticancer effects and is expected to become a new strategy against TNBC. In our research, cell viability, colony formation, flow cytometry, Western blot, and tumor xenograft model assays were established to evaluate the suppression effect of PL and DOX alone and in combination. Data showed tha...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Five-year breast cancer (BC) survival rates have increased dramatically over the past several decades (DeSantis et al., 2016). Yet, many women continue to report persistent adverse symptoms that they attribute to their breast cancer treatment; in particular the effects of chemotherapy (Dodd et al., 2010). Commonly reported symptoms include cognitive difficulties and fatigue that is often described as extreme exhaustion that interferes with daily activities (Abrahams et al., 2016; Bray et al., 2018; Manir et al., 2012; Yang and Hendrix, 2018).
Source: Journal of Neuroimmunology - Category: Allergy & Immunology Authors: Source Type: research
We report that the combination of anti‐ZNF703 RNAi with ibuprofen as the inhibitor of COX‐2 is highly effective in inhibiting MCF‐7 as a breast cancer cell line and shows therapeutic potential for breast cancer.
Source: Biotechnology and Applied Biochemistry - Category: Biochemistry Authors: Tags: Original Article Source Type: research
More News: Avastin | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Women